BioLineRx (BLRX) Earnings Date, Estimates & Call Transcripts $3.56 -0.08 (-2.20%) Closing price 03:58 PM EasternExtended Trading$3.53 -0.03 (-0.87%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BioLineRx Earnings Summary BioLineRx released Q3 2024 earnings on November 25, 2024, reporting an EPS of -$2.80, which beat the consensus estimate of -$3.20 by $0.40. With a trailing EPS of -$8.80, BioLineRx's earnings are expected to grow next year, from ($5.80) to ($5.60) per share. Upcoming Q4 Earnings DateMay. 27Before Market OpensEstimatedConsensus EPS (Nov. 25) -$3.20 Actual EPS (Nov. 25) -$2.80 Beat By $0.40 Q3 2024 Earnings ResourcesQ3 2024 Earnings ReportConference Call Transcript & Audio Press Release (8-K)BLRX Upcoming EarningsBioLineRx's Q1 2025 earnings is scheduled for Tuesday, May 27, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportPowered by Get BioLineRx Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioLineRx and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataBLRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.BLRX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. BioLineRx Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.84-$0.84-$0.84Q2 20251-$0.77-$0.77-$0.77Q3 20251-$0.92-$0.92-$0.92Q4 20251-$0.99-$0.99-$0.99 BioLineRx Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/27/2025(Estimated)-------11/25/2024Q3 2024-$3.20-$2.80+$0.40-$0.07--11/25/2024Q3 2024-$3.20-$2.80+$0.40-$0.07--8/15/2024Q2 2024-$3.20$0.40+$3.60$0.01$3.93M$5.39M5/28/2024Q1 2024-$11.60-$0.40+$11.20-$0.01$0.34M$6.86M3/28/2024Q4 2023-$8.80-$6.00+$2.80-$0.15$0.17M$4.80M11/20/2023Q3 2023-$7.20-$12.00 -$4.80-$0.30--8/30/2023Q2 2023-$6.40-$12.00 -$5.60-$0.30--5/24/2023Q1 2023-$5.60-$6.00 -$0.40-$0.15-- BioLineRx Earnings - Frequently Asked Questions When is BioLineRx's earnings date? BioLineRx has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 27th, 2025 based off last year's report dates. Learn more on BLRX's earnings history. Did BioLineRx beat their earnings estimates last quarter? In the previous quarter, BioLineRx (NASDAQ:BLRX) reported ($2.80) earnings per share (EPS) to beat the analysts' consensus estimate of ($3.20) by $0.40. Learn more on analysts' earnings estimate vs. BLRX's actual earnings. How can I listen to BioLineRx's earnings conference call? The conference call for BioLineRx's latest earnings report can be listened to online. Listen to Conference Call How can I read BioLineRx's conference call transcript? The conference call transcript for BioLineRx's latest earnings report can be read online. Read Transcript How much revenue does BioLineRx generate each year? BioLineRx (NASDAQ:BLRX) has a recorded annual revenue of $28.94 million. How much profit does BioLineRx generate each year? BioLineRx (NASDAQ:BLRX) has a recorded net income of -$60.61 million. BLRX has generated -$8.80 earnings per share over the last four quarters. What is BioLineRx's EPS forecast for next year? BioLineRx's earnings are expected to grow from ($5.80) per share to ($5.60) per share in the next year. More Earnings Resources from MarketBeat Related Companies RNTX Earnings Date RNXT Earnings Date ATRA Earnings Date PRLD Earnings Date XLO Earnings Date SCYX Earnings Date ACRV Earnings Date BRNS Earnings Date ESLA Earnings Date ALZN Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds This page (NASDAQ:BLRX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
